pISSN 1976-2283
eISSN 2005-1212

Download original image
Fig. 3. Short-term results for (A) clinical remission, (B) clinical response, (C) mucosal healing, and (D) inflammatory bowel disease questionnaire (IBDQ) response in patients exposed to adalimumab versus placebo.

CI, confidence interval.

Gut and Liver 2016;10:262~274 https://doi.org/10.5009/gnl15042
© Gut and Liver